Navigation Links
BioMS Medical Announces Second Quarter 2008 Results
Date:8/12/2008

ated net loss of $24.6 million or ($0.31) per share for the same period of 2007.

Revenue for the three months ended June 30, 2008 was $11.2 million compared to $nil for the same period of 2007. Revenue for the six months ended June 30, 2008 was $24.0 million compared to $nil for the same period of 2007. The revenue is the result of recognizing a portion of the upfront payment received on the completion of the licensing agreement with Eli Lilly and Company.

Total consolidated expenses for the three months ended June 30, 2008 were $11.4 million compared to $12.1 million for the same period of 2007. Total consolidated expenses for the six months ended June 30, 2008 were $33.6 million compared to $25.4 million for the period of 2007.

Research and development expenses for the three months ended June 30, 2008 totaled $9.3 million compared to $10.2 million for the three months ended June 30, 2007. It is expected that total research and development expenses will remain constant over the next two years as the MAESTRO-01 and MINDSET-01 clinical trials near completion and MAESTRO-02 and MAESTRO-03 increase in number of patients under treatment. General and administrative expenses were $1.7 million for the three months ended June 30, 2008 compared to $1.5 million for the three months ended June 30, 2007.

At June 30, 2008, cash and short-term investments totaled $96.1 million as compared to $38.0 million at December 31, 2007. At June 30, 2008, the Corporation had working capital of $93.1 million (excluding the current portion of deferred revenue which does not represent a cash obligation) as compared to $34.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Corporation to meet its obligations in respect of the currently initiated clinical trials for which it is responsible under the Lilly agreement.

As at June 30, 2008 there were 91,163,323 common shares of the Corporation issued and outs
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  US-Australian drug discovery company, Novogen Limited (ASX: ... comprehensive scientific review has identified high value opportunities ... unmet patient need. Novogen is moving as quickly ... to entering into Phase 1 clinical trials with ... Executive Officer, Iain Ross , said that ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a ... Annual High Tech Awards. , Now in its 22nd year, this premier awards ... innovation here, across the nation and around the world. The OC Tech Alliance will ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... presented two studies at the International Spine Intervention Society’ s 23rd ... through to August 1st, 2015. With a focus on evidence-based research and clinical ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4
... may seem obvious that dunking relatively spherical objects in ... will result in an array of completely encapsulated berries. ... have similarly dunked their wares in protective coatings in ... chemical interactions with solvents. Unfortunately, reactions in the ...
... Beta-Pro LLC, announced today that it has expanded ... drug discovery and research institutes in the $2 ... now manages extensive laboratory facilities in the University ... "Beta-Pro has already established a foothold ...
... US Oncology, Inc., the nation,s leading integrated oncology ... patient in a Phase I clinical trial through its ... trials present special challenges, including increased safety concerns, higher ... some first-in-human trials, making Phase I trials more difficult ...
Cached Biology Technology:Nanoscopic particles resist full encapsulation, Sandia simulations show 2Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... St. Louis, July 31, 2008 Staying awake slows down ... its peak after sleep but inevitably trends downward throughout the ... For the first time, researchers at Washington University School of ... this downward slide. When scientists genetically tweaked a part of ...
... Michigan State University researcher and his students have ... and stronger and could result in more fuel-efficient ... medical and sports equipment. The material ... in the development of new and expanded applications ...
... Auckland, New Zealand - Kiwifruit lovers can look forward ... to the release this week of crucial genetic data ... new varieties with increased health properties and exciting colours ... company HortResearch and listed New Zealand biotech company Genesis ...
Cached Biology News:Brain tweak lets sleep-deprived flies stay sharp 2'Small' research at MSU leads to advances in energy, electronics 2Genetic data promises new future for kiwi fruit 2Genetic data promises new future for kiwi fruit 3
Human Legumain Affinity Purified Polyclonal Ab...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Human Cystatin F MAb (Clone 292103)...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
Biology Products: